Cargando…
Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo
The vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) axis is an essential regulator of angiogenesis and important therapeutic target in cancer. Ramucirumab is an anti-VEGFR2 monoclonal antibody used for the treatment of several cancers. Increased circulating VEGF-A levels after ramuci...
Autores principales: | Mashima, Tetsuo, Wakatsuki, Takeru, Kawata, Naomi, Jang, Myung-Kyu, Nagamori, Akiko, Yoshida, Haruka, Nakamura, Kenichi, Migita, Toshiro, Seimiya, Hiroyuki, Yamaguchi, Kensei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302577/ https://www.ncbi.nlm.nih.gov/pubmed/34302038 http://dx.doi.org/10.1038/s41598-021-94584-9 |
Ejemplares similares
-
Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2016) -
In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells
por: Mashima, Tetsuo, et al.
Publicado: (2019) -
ALDH1A3‐mTOR axis as a therapeutic target for anticancer drug‐tolerant persister cells in gastric cancer
por: Kawakami, Ryuhei, et al.
Publicado: (2020) -
mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer
por: Mashima, Tetsuo, et al.
Publicado: (2017) -
Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)